RA CAPITAL MANAGEMENT

200 Berkeley Street
Boston, MA 2116

Website: racap.com

Firm Size

• Assets Under Management (AUM):$9.5 Billion
• Employees:122
• Firm Type:Venture Capital
• Focus Areas: Software & Technology
  Healthcare
  

Description

RA Capital Management, LP is a prestigious investment firm located in Boston, Massachusetts. Established in 2001 by Peter Kolchinsky, this firm specializes in funding breakthrough medical technologies and healthcare companies. RA Capital operates with a long-term and flexible investment strategy, seeking to support innovative healthcare solutions that have the potential to transform patient care and make a significant impact in the industry. Their investment approach focuses on early-stage ventures, drug development, and medical research. The firm has a team of experienced professionals with expertise in healthcare investing, scientific research, and business development. They utilize their deep industry knowledge to make informed investment decisions and provide valuable guidance and support to their portfolio companies. RA Capital manages a diverse portfolio, consisting of both public and private investments in the healthcare sector. They actively seek out opportunities in biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health, among other areas. With a strong track record of success, RA Capital has established itself as a trusted partner for medical innovation. Their investments have resulted in numerous breakthroughs and advancements in healthcare, benefiting both patients and investors. Overall, RA Capital Management, LP is a prominent investment firm in Boston that contributes to the advancement of healthcare through strategic investments in cutting-edge medical technologies and innovative healthcare companies.

Latest News

Powered by

May 29, 2024: Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline
Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a second Series A extension financing, raising a total of 98M EUR . This additional 16M EUR financing was led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors Novo Holdings, Ysios Capital, RA Capital Management, HealthCap, Gilde Healthcare and Pontifax Venture Capital. As part of the investment, Iyona Rajkomar, Managing Partner at Dawn Biopharma, will join the Adcendo Board of Directors.

Apr 10, 2024: TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline


Mar 12, 2024: Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The oversubscribed financing includes participation from new and existing institutional investors, including Adage Capital Partners L.P., Deep Track Capital, the Federated Hermes Kaufmann Funds, New Enterprise Associates (NEA), Octagon Capital, RA Capital Management, and Vivo Capital. Upon the closing of the financing, which is anticipated to occur on or about March 14, 2024, the Company expects to receive gross proceeds of approximately $100 million . The closing of the financing is subject to customary closing conditions.

Feb 29, 2024: Avidity Biosciences Announces Oversubscribed $400 Million Private Placement


Feb 13, 2024: ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage Antibody-Drug Conjugate (ADC) Pipeline


Feb 02, 2024: Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the PIPE) for gross proceeds of approximately $200 million .

Dec 04, 2023: AM Batteries Closes $30M Series B led by Toyota Ventures to Accelerate the Commercialization of its Dry Battery Electrode Technology
AM Batteries , a pioneer in the field of lithium-ion dry-electrode technologies, today announced it closed a $30M Series B in an oversubscribed funding round led by Toyota Ventures. New investment combines strategic corporate support from Porsche Ventures and Asahi Kasei, with financial investment from RA Capital Management - Planetary Health, Wilson Sonsini , and Industry Ventures. The round also includes existing investors such as Anzu Partners, TDK Ventures, Creative Ventures, Doral Energy-Tech Ventures, Foothill Ventures, and Zeon Ventures.

Nov 08, 2023: Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Immune Therapies
 Forward Therapeutics, Inc., a biopharmaceutical company developing next-generation small molecule therapies for chronic immunological and inflammatory disorders, today announced a $50 million Series A financing. The financing was led by BVF Partners LP with participation from other leading life sciences investors RA Capital Management and OrbiMed.

Oct 09, 2023: Commons Clinic Announces $19.5M Series A Financing to Unseat Specialty Care Incumbents With its New Model for Spinal Care, Orthopedics, and Pain Management
Commons Clinic , the branded, value-based health system offering all-inclusive, expert care for spine, orthopedics, and pain management, today announced its $19.5M Series A financing led by RA Capital Management with participation from existing investors Floating Point and Courtside Ventures as well as new investor Time BioVentures. Today's financing brings Commons Clinic's total funding to $33.5M including investments from industry-pioneering angels such as Elliot Cohen (Co-Founder, Pillpack), Mike West (former CEO, Rothman Orthopedics ), and founders from Cityblock Health, CityMD, PatientPing, Elemy and more. This round of financing sees Commons Clinic add two new board members, Prithviraj Singha Roy of RA Capital Management and John Loser of Floating Point, who join Nick Aubin , co-founder and CEO, Paulo da Costa , co-founder and COO, and Bob Badal , co-founder of Strive Health. Commons Clinic is a branded, independent, value-based health system ushering in a new era of service that isn't held hostage by today's stagnant hospital-centric model.

Sep 25, 2023: Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach
 Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a genome-wide methylome approach, announced today the closing of $48 million in financing. In addition, the company announced that Lisa Alderson will join Adela as interim Chief Executive Officer (CEO), succeeding Dr. Scott Bratman . Dr. Bratman will continue to serve as a member of Adela's Board of Directors and as President.

Aug 30, 2023: Sortera Technologies Closes $30.5 Million in New Funding to Fully Commercialize Its State-of-the-Art Upcycling Facility
Sortera Technologies, Inc.,  an innovative material sorting company with a recycling platform powered by artificial intelligence, data analytics, and advanced sensors, today announced the close of a $30.5 million Series C funding round led by RA Capital Management-Planetary Health with participation from certain funds and accounts advised by T. Rowe Price Associates, Inc., the Mineral Resources Group, which is a part of Mitsubishi Corporation's Business Incubation Unit, and Macquarie GIG Energy Transition Solutions ("MGETS"). Additional existing investors include Assembly Ventures, Breakthrough Energy Ventures, and Chrysalix. This funding will fuel Sortera's growth as a major player in the domestic upcycling space. Additionally, it will help to affirm the company's commitment to solutions that create new upcycling streams, enable a circular economy, and contribute to a more sustainable future.

Aug 29, 2023: Inhibrx Announces $200 Million Private Placement Financing
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has entered into a securities purchase agreement for a private placement financing (the "PIPE") that is expected to result in gross proceeds of approximately $200 million . The financing was limited to certain of the Company's existing investors, which included participation from RA Capital Management as the lead investor, Viking Global Investors, Perceptive Advisors, and TCGX.

Aug 24, 2023: ExcepGen Emerges From Stealth with New Funding for its Nucleic Acid Therapeutics Platform
ExcepGen, a genetic medicine startup, emerged from stealth after the successful completion of its newest funding round. The most recent $4 million round, which brings the company's total seed funding to $14 million , was led by RA Capital Management and backed by Gravity Fund, Apollo Projects ( Sam Altman ), and other premier investors.

Aug 07, 2023: Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
Gracell Biotechnologies Inc. ("Gracell" or the "Company", Nasdaq: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it has entered into a purchase agreement with a select group of institutional and accredited healthcare specialist investors for the private placement of (i) 138,900,000 ordinary shares of the Company (the "Ordinary Shares") (equivalent to 27,780,000 of the Company's American depositary shares ("ADSs")), at a purchase price equivalent to $3.60 per ADS, and (ii) warrants to purchase up to 44,802,870 Ordinary Shares (equivalent to 8,960,574 ADSs) (the "Warrants") at an exercise price equivalent to $5.58 per ADS, representing a 55% premium to the purchase price of Ordinary Shares.  Gracell will receive $100 million in proceeds from the private placement of Ordinary Shares, and up to an additional $50 million if the Warrants are fully exercised.  The Warrants will remain exercisable at the election of the investors within 24 months after the closing of the private placement. The financing is expected to close on August 10, 2023 , subject to customary closing conditions.

Jul 10, 2023: SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases